Ishiguro, Hiroshi <br/><br/>
A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).  [electronic resource] 

 -  Cancer medicine  Dec 2017 
 - 2909-2917 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.1258  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, CD34--blood<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Camptothecin--administration & dosage<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Drug Combinations<br/>Endothelial Progenitor Cells--drug effects<br/>Female<br/>Gene Frequency<br/>Glucuronosyltransferase--genetics<br/>Heterozygote<br/>Homozygote<br/>Humans<br/>Irinotecan<br/>Japan<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local<br/>Oxonic Acid--administration & dosage<br/>Pharmacogenetics<br/>Pharmacogenomic Variants<br/>Phenotype<br/>Tegafur--administration & dosage<br/>Treatment Outcome